Evidence map›Paper›PMID 38581458›Full record

ArticleInternational journal of hematology2024

Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid.

Yusuke Inoue, Asuka Oda, Yusaku Maeda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Shiro Fujii, Shingen Nakamura and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Efficient multiplex non-viral engineering and expansion of polyclonal γδ CAR-T cells for immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Yusuke InoueDepartment of Medical Technology, Tokushima University Hospital, Tokushima, Japan.
Asuka OdaDepartment of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, 770-8503, Japan.
Yusaku MaedaDepartment of Hematology, Tokushima University Hospital, Tokushima, Japan.
Ryohei SumitaniDepartment of Hematology, Tokushima University Hospital, Tokushima, Japan.
Masahiro OuraDepartment of Hematology, Tokushima University Hospital, Tokushima, Japan.
Kimiko SogabeDepartment of Hematology, Tokushima University Hospital, Tokushima, Japan.
Tomoko MaruhashiDepartment of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, 770-8503, Japan.
Mamiko TakahashiDepartment of Hematology, Tokushima University Hospital, Tokushima, Japan.
Shiro FujiiDepartment of Hematology, Tokushima University Hospital, Tokushima, Japan.
Shingen NakamuraDepartment of Community Medicine and Medical Science, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Hirokazu MikiDivision of Transfusion Medicine and Cell Therapy, Tokushima University Hospital, Tokushima, Japan.
Masahiro HiasaDepartment of Orthodontics and Dentofacial Orthopedics, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Jumpei TeramachiDepartment of Oral Function and Anatomy, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Takeshi HaradaDepartment of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, 770-8503, Japan. takeshi_harada@tokushima-u.ac.jp.ORCID http://orcid.org/0000-0002-3997-7471
Masahiro AbeDepartment of Hematology, Kawashima Hospital, Tokushima, 770-0011, Japan. masabe@tokushima-u.ac.jp.
Tokushima University Hospital · JPTokushima University · JPOkayama University · JP

Funding

Japanese Society of Hematology 23195Japan Society for the Promotion of Science 21H03111Japan Society for the Promotion of Science 22K19626Japan Society for the Promotion of Science JP17H05104Japan Society for the Promotion of Science JP19K22719Japan Society for the Promotion of Science JP22K08455Japan Society for the Promotion of Science JP23H03101University of Tokushima 2202003
6 · The paper itself

Abstract

As multiple myeloma (MM) progresses, immune effector cells decrease in number and function and become exhausted. This remains an insurmountable clinical issue that must be addressed by development of novel modalities to revitalize anti-MM immunity. Human Vγ9Vδ2 T (Vδ2

Indexed as

DiphosphonatesImidazolesLymphocyte ActivationMultiple MyelomaReceptors, Antigen, T-Cell, gamma-deltaThalidomideZoledronic AcidAdaptor Proteins, Signal TransducingAntigens, CDButyrophilinsCell ProliferationHumansInterleukin-2LenalidomideLeukocytes, MononuclearTh1 CellsAdaptor Proteins, Signal TransducingAntigens, CDBTN3A1 protein, humanButyrophilinsDiphosphonatesImidazolesInterleukin-2LenalidomidepomalidomideReceptors, Antigen, T-Cell, gamma-deltaThalidomideUbiquitin-Protein LigasesZoledronic AcidCELMoDImmunotherapyMultiple myelomaVγ9Vδ2 T cellZoledronic acid

Identifiers

PMID38581458
OpenAlexW4394011496

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.